Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharma (NQ: PIRS )

0.3200 -0.0060 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pieris Pharma

< Previous 1 2 Next >
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Via ACCESSWIRE
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Via ACCESSWIRE
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Via ACCESSWIRE
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Via ACCESSWIRE
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Via ACCESSWIRE
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Via ACCESSWIRE
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Via ACCESSWIRE
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
Via ACCESSWIRE
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Via ACCESSWIRE
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
Via ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Via ACCESSWIRE
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
Via ACCESSWIRE
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
Via ACCESSWIRE
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST - Initiated efficacy part of phase 2a study of PRS-060/AZD1402; expected topline readout this year - Dosed first... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin®... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.